Nuclidium AG
Im Erasmushaus,
Bäumleingasse 18,
4051 Basel,
Switzerland
Nuclidium (DE) GmbH
Prinzregentenstr. 64,
81675 München,
Germany
Setting a
New Standard in
Precision Oncology
Next-generation copper-based radiopharmaceuticals enable the highest accuracy and accessibility for targeted cancer treatment
Precision pipeline
Delivering superior precision oncology treatments to patients with diverse high-need tumour indications
Secured Production Process & Broad Distribution Network
Overcoming current limitations for targeted radiopharmaceuticals at highly advantageous economics
About Us
A precise and targeted treatment saves lives:
NUCLIDIUM AG is a clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – NUCLIDIUM is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. Our goal is to deliver scalable, accessible, and clinically superior theranostic solutions to patients worldwide.
Addressing the Unmet Need in Major Oncology Indications with Disruptive Treatments
Why Do We Need Better Radiopharmaceuticals?
The quality of life and survival rates of cancer patients critically depend on a precise diagnosis and treatment. Recent technological advancements have made radiopharmaceuticals a promising regimen in precision oncology. However, to unleash their full potential, several challenges and limitations need to be addressed:
Improving Survival
50% of cancer patients are misdiagnosed severly impacting survival & quality of life. €3bn loss/year through misdiagnosis of common cancer types
Current Diagnostics
Current radiodiagnostics do not cover diagnosis/staging and follow-up for different tumor types in one product
High Costs
Different radiometals in diagnosis and treatment require elaborate manufacturing and supply networks with high technology costs
Target Molecules
Different target molecules between diagnostics and therapeutic prevent accurate assessment of biodistribution and dosimetry